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 Rationale: Carnitine palmitoyltransferase (CPT) II is one of a pivotal enzyme in 
mitochondrial fatty acid oxidation, which is essential for energy production during 
simultaneous glucose sparing and a requirement for major energy supply, such as 
prolonged fasting or exercise. When infants require more energy than provided by the 
glycolytic system, they rely on the mitochondrial fatty acid oxidation pathway. 
Mutations of the CPT2 gene have been reported to cause sudden unexpected death 
in infancy (SUDI). A thermolabile phenotype of a CPT2 polymorphism (F352C) has 
been recently reported to reduce CPT II enzyme activity. The F352C variant results in 
energy crisis at high temperature and is suspected as a risk factor for acute 
encephalopathy. However, a relationship between CPT2 gene polymorphism and 
SUDI has not been described. Methods: Single nucleotide polymorphisms of the 
CPT2 gene were investigated among 54 SUDI cases and 200 healthy volunteers. 
Results: The frequency of the C allele was significantly higher in the SUDI group than 
in the control group [25.0% vs 16.0%, odds ratio (OR) = 1.75, 95% confidence interval 
(CI) = 1.05–2.92, p = 0.030). The frequency of the F352C homozygote was 
significantly higher in the SUDI group than in control group (11.1% vs 3.5%, OR = 
 3 
3.45, 95% CI = 1.11–10.73, p = 0.036). Conclusion: The F352C CPT2 variant might 
be a genetic risk factor for SUDI. 
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 Mitochondrial fatty acid oxidation is essential for energy production during 
conditions requiring simultaneous glucose sparing and a major energy supply, such 
as prolonged fasting or exercise. An essential step in fatty acid oxidation is played by 
the carnitine palmitoyltransferase (CPT) enzyme system, which transfers long-chain 
fatty acids containing ≥16 carbons (C16, C18:1, C18:2, and C18) from the cytosolic 
compartment to the mitochondrial matrix, where β-oxidation takes place. The CPT 
enzyme system consists of several mitochondrial membrane-bound enzymes: CPT I, 
CPT II (EC 2.3.1.21), and carnitine-acylcarnitine translocase. CPT II is located on the 
inner aspect of the inner mitochondrial membrane and converts long-chain 
acylcarnitines to long-chain acyl-CoAs [1–3]. 
 Carnitine palmitoyltransferase II deficiency is one of the most common inherited 
metabolic disorders and is categorized into three forms: neonatal (OMIM 608836) [5], 
infantile (OMIM 600649) [5], and adult (OMIM 255110) [6]. The infantile form usually 
manifests at 6–24 months of age as recurrent attacks of hypoketotic hypoglycemia, 
resulting in coma and seizures, liver failure, and transient hepatomegaly. About half of 
cases have heart involvement with cardiomyopathy and arrhythmia, and some result 
in sudden unexpected death in infancy (SUDI). The neonatal form is more severe 
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than the infantile form. Many sudden death cases are reported, most often during the 
first month of life [1–3,7,8]. 
 Various mutations of the CPT2 gene have been reported and some of the more 
severe mutations are fatal [1–3]. Carnitine palmitoyltransferase 2 gene 
polymorphisms have not been reported to affect enzyme activity, although a 
thermolabile phenotype of the CPT2 polymorphism (F352C) has been recently 
reported to reduce enzyme activity at high temperature [9–11]. Shinohara et al. have 
reported that the F352C variant causes energy crisis at high temperature and is 
associated with acute encephalopathy [12]. The F352C variant is therefore a genetic 
risk factor for acute encephalopathy. 
 Various environmental and genetic risk factors have been associated with SUDI. 
Serotonin transporter, cardiac ion channel, autonomic nervous system, and 
complement or interleukin polymorphisms have been reported as genetic risk factors, 
while smoking, prone or side sleeping, soft bedding, and prematurity are recognized 
as environmental risk factors [13,14]. However, to our knowledge, a relationship 
between CPT2 gene polymorphism and SUDI has not been described. 
 Under heat stress, fasting, acidosis, or seizures, moderately reduced CPT II activity 
due to the F352C variant may accelerate the disease process of acute 
encephalopathy [11]. Therefore, infants who have the F352C variant may be more 
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vulnerable to energy crisis than those without the polymorphism, leading to a 
hypothetical risk of SUDI. 
 In the present study, we conducted a single nucleotide polymorphism (SNP) 
analysis of the CPT2 gene among the SUDI group in order to determine whether the 
F352C variant might be a genetic risk factor for SUDI or not. 
 
2. Materials and methods 
 
 This study was approved by the Ethics Committee of the Nagasaki University 
Graduate School of Medicine and Osaka University Graduate School of Medicine. 
 
2.1. Study population 
 
 We retrospectively reviewed 54 SUDI cases at ages ranging from 1 day to 10 
months (30 male; 24 female), whose causes of death were unexplained after 




2.2 Extraction of genomic DNA and polymorphism analysis 
 
 Genomic DNA was purified from frozen blood samples with the PureLink™ 
Genomic DNA kit (Invitrogen, Grand Island, NY) according to the manufacturer’s 
instructions. Exon 4 of the CPT2 gene was then amplified, followed by polymerase 
chain reaction (PCR) reactions performed in a 25-µL volume containing 12.5 µL of 
PrimeSTAR Max Premix (2×) (Takara, Otsu, Japan), 0.4 µM each of the primers 
(Forward; 5'-CAGTGTTCTGTCTCTGCCTA-3', Reverse; 
5'-GCCTCCTCTCTGAAACTGGA-3'), and 200 ng of template DNA under the 
following conditions: 98.0˚C for 1 min, 30 cycles of 98.0˚C for 10 sec, 54.0˚C for 5 sec, 
and 72.0˚C for 30 sec, and finally 72.0˚C for 5 min. PCR products were sequenced 
with the BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster 
City, CA) on an Applied Biosystems 3730 DNA Analyzer (Applied Biosystems) 
according to the manufacturer’s instructions. Sequences from the 5' ends were 
confirmed by comparison with those from the 3' ends at least twice independently and 
each sequence was compared with the standard sequence (GenBank accession 
number: CPT2: NM_000098.2). 
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2.3 Haplotype analysis of the CPT2 gene 
 
 When two heterozygous genotypes (c.1055T>G [p.F352C] and c.1102G>A 
[p.V368I]) in CPT2 exon 4 were recognized, cloning was performed. The PCR 
products were amplified with a pair of primers. Next, we performed reconditioning 
PCR in order to avoid heteroduplexes from mixed-template PCR products [15]. After 
the PCR products were obtained, they were diluted 10-fold into a fresh reaction 
mixture of the same composition and cycled three times. The PCR products were 
purified from agarose gel and cloned into the pCR®-Blunt II-TOPO® vector (Invitrogen), 
and the resulting constructs were transformed into Competent high DH5α cells 
(Toyobo, Osaka, Japan). Colonies were selected and analyzed on kanamycin agar 
and the plasmid inserts were sequenced using the M13 Forward primer and the M13 
Reverse primer (Invitrogen). 
 
2.4 Genotyping of healthy individuals 
 
 Two hundred healthy Japanese volunteers (Non-SUDI control group, whose ages 
were over 20 years old) were subjected to genotyping by direct sequencing in the 
same manner as described above. 
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2.5 Statistical analysis 
 
 Allele frequencies were derived from gene counts, and differences between the 
SUDI and the control groups were evaluated by χ2-tests or the Fisher’s exact test. 
Significant differences were defined as p < 0.05 in conditional analysis. Odds ratios 
(ORs) and 95% confidence intervals (CIs) were calculated to evaluate the effects of 




 Two CPT2 polymorphisms (c.1055T>G [p.F352C] and c.1102G>A [p.V368I]) of the 
CPT2 gene were found in the SUDI and the control groups. Chen et al. have 
previously detected three polymorphisms (F352C, V368I, and M647V), which were 
classified into nine genotypes [9]. M647V is irrelevant to enzyme activity and we did 
not investigate exon 5 where it is located. Six genotypes were therefore classified in 
the present study and their distribution among the SUDI and the control groups is 
shown in Table 1. F352C is the Asian-specific variant and has not been reported in 
Caucasians and several genetic distribution has been reported so far [12,16]. The 
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genotypic distribution among controls in the present study was not significantly 
different (p = 0.704) from that for one of the previously reported data [12] and is 
consistent with the general genotypic distribution among the Japanese population. 
The most frequent genotype was FV–FI (type C) in both the SUDI and the control 
groups. Genotypic distribution was not significantly different (p = 0.266) between the 
SUDI and the control groups (Table 1). 
 The allelic frequencies of F352C and V368I are shown in Table 2. The frequency of 
the C allele was higher in the SUDI group compared to the control group (25.0% vs 
16.0%). The frequency of F352C was significantly higher in the SUDI group compared 
to the control group (OR = 1.75, 95% CI = 1.05–2.92, p = 0.030), while the frequency 
of V368I was not significantly different between the SUDI and the control groups (OR 
= 0.97, 95% CI = 0.61–1.55, p = 0.898). 
 The numbers of CI alleles in the SUDI and the control groups is shown in Table 3. 
The frequency of having a CI allele was not significantly different between the SUDI 
and the control groups (p = 0.060). 
 The frequency of wild/heterozygocity or homozygocity for F352C is shown in Table 
4. The frequency of the F352C homozygote was significantly higher in the SUDI group 





 It is well known that some mutations of the CPT2 gene decrease CPT II activity and 
cause CPT II deficiency. While CPT2 gene polymorphisms do not decrease CPT II 
activity in normal physiological situations, the F352C variant alone has been reported 
to reduce CPT II activity by about 50% under certain conditions such as heat stress, 
fasting, acidosis, and seizures [9–11,17]. Shinohara et al. has reported that the F352C 
variant is a statistically significant risk factor in patients with acute encephalopathy 
[12]. 
 Sudden unexpected death in infancy is defined as sudden unexpected death 
occurring before 12 months of age. The common causes of SUDI are infection, 
cardiovascular anomaly, child abuse, and metabolic disorders. However, any 
background genetic risk factors for SUDI currently remain unknown. 
 In the present study, we found that the F352C allele was significantly higher among 
the SUDI group compared to the control group. Haplotype analysis revealed no 
difference, but the frequency of the F352C homozygote was significantly higher in the 
SUDI group than in the control group. 
 The in vitro expression of the F352C variant in COS-7 cells is <30% of the wild type 
at high temperature [9]. A congenital or acquired abnormality of mitochondrial fatty 
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acid oxidation causes the accumulation of mini-plasmin in the cerebral capillaries and 
the proteolytical destruction of the blood–brain barrier in mice after influenza virus 
infection [9,18]. Intracellular ATP production is reduced by about 50% for the F352C 
variant compared to the wild type under severe conditions [9–11,17]. The suppression 
of intracellular ATP production weakens interactions between tight junction proteins of 
cerebral microvascular endothelial cells, leading to the destruction of brain 
homeostasis and brain edema [10]. Thus, under severe conditions such as high fever 
and respiratory or metabolic acidosis, decreased CPT II activity with the F352C 
variant might lead to energy crisis, acute brain edema, and sudden death. 
 We have previously performed metabolic autopsy among SUDI cases and found 
some inherited metabolic disorders [19]. However, in some SUDI cases, even after 
thorough investigations, we could sometimes find only negligible pathological 
abnormalities. In these cases, if they had a genetic risk factor, even a negligible 
abnormality might trigger an energy crisis and might lead to death. In fact, we had 
experienced one girl patient with the F352C variant, whose long-chain acylcarnitines 
had been distinctly increased [19]. We cannot confirm the reason of the increase, but 
the F352C variant possibly might have affected it. 
 In conclusion, we found that the F352C variant was statistically higher among the 
SUDI group compared to the control group in our case-control study. The F352C 
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variant has been associated with acute encephalopathy after viral infection [12]. In the 
present study, we suggest that the F352C variant is also related to SUDI. The F352C 
CPT2 variant would therefore appear to be a genetic risk factor for SUDI. Further 




 We gratefully thank Tatsuya Tanaka and Mitsuru Yamanaka for their DNA 





[1]  Bonnefont JP, Demaugre F, Prip-Buus C, Saudubray JM, Brivet M, Abadi N, et 
al. Carnitine palmitoyltransferase deficiencies. Mol Genet Metab 
1999;68:424–40. 
[2]  Sigauke E, Rakheja D, Kitson K, Bennett MJ. Carnitine palmitoyltransferase II 
deficiency: a clinical, biochemical, and molecular review. Lab Invest 
2003;83:1543–54. 
[3]  Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J. Carnitine 
palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol 
Aspects Med 2004;25:495–520. 
[4]  Hug G, Bove KE, Soukup S. Lethal neonatal multiorgan deficiency of carnitine 
palmitoyltransferase II. N Engl J Med 1991;325:1862–4. 
[5]  Demaugre F, Bonnefont JP, Colonna M, Cepanec C, Leroux JP, Saudubray JM. 
Infantile form of carnitine palmitoyltransferase II deficiency with hepatomuscular 
symptoms and sudden death. Physiopathological approach to carnitine 
palmitoyltransferase II deficiencies. J Clin Invest 1991;87:859–64. 
[6] DiMauro S, DiMauro PM. Muscle carnitine palmityltransferase deficiency and 
myoglobinuria. Science 1973;182:929–31. 
 15 
[7]  Longo N, Amat di San Filippo C, Pasquali M. Disorders of carnitine transport and 
the carnitine cycle. Am J Med Genet C Semin Med Genet 2006;142C:77–85. 
[8] Kompare M, Rizzo WB. Mitochondrial fatty-acid oxidation disorders. Semin 
Pediatr Neurol 2008;15:140–9. 
[9] Chen Y, Mizuguchi H, Yao D, Ide M, Kuroda Y, Shigematsu Y, et al. 
Thermolabile phenotype of carnitine palmitoyltransferase II variations as a 
predisposing factor for influenza-associated encephalopathy. FEBS Lett 
2005;579:2040–4. 
[10] Yao D, Mizuguchi H, Yamaguchi M, Yamada H, Chida J, Shikata K, et al. 
Thermal instability of compound variants of carnitine palmitoyltransferase II and 
impaired mitochondrial fuel utilization in influenza-associated encephalopathy. 
Hum Mutat 2008;29:718–27. 
[11] Kubota M, Chida J, Hoshino H, Ozawa H, Koide A, Kashii H, et al. Thermolabile 
CPT II variants and low blood ATP levels are closely related to severity of acute 
encephalopathy in Japanese children. Brain Dev 2012;34:20–7. 
[12] Shinohara M, Saitoh M, Takanashi J, Yamanouchi H, Kubota M, Goto T, et al. 
Carnitine palmitoyl transferase II polymorphism is associated with multiple 
syndromes of acute encephalopathy with various infectious diseases. Brain Dev 
2011;33:512–7. 
 16 
[13] Moon RY, Horne RS, Hauck FR. Sudden infant death syndrome. Lancet 
2007;370:1578–87. 
[14] Narita N, Narita M, Takashima S, Nakayama M, Nagai T, Okado N. Serotonin 
transporter gene variation is a risk factor for sudden infant death syndrome in the 
Japanese population. Pediatrics 2001;107:690–2. 
[15] Thompson JR, Marcelino LA, Polz MF. Heteroduplexes in mixed-template 
amplifications: formation, consequence and elimination by 'reconditioning PCR'. 
Nucleic Acids Res 2002;30:2083–8. 
[16] Wataya K, Akanuma J, Cavadini P, Aoki Y, Kure S, Invernizzi F, et al. Two CPT2 
mutations in three Japanese patients with carnitine palmitoyltransferase II 
deficiency: functional analysis and association with polymorphic haplotypes and 
two clinical phenotypes. Hum Mutat 1998; 11:377-86. 
[17] Olpin SE, Afifi A, Clark S, Manning NJ, Bonham JR, Dalton A, et al. Mutation and 
biochemical analysis in carnitine palmitoyltransferase type II (CPT II) deficiency. 
J Inherit Metab Dis 2003;26:543–57. 
[18] Yao D, Chen Y, Kuwajima M, Shiota M, Kido H. Accumulation of mini-plasmin in 
the cerebral capillaries causes vascular invasion of the murine brain by a 
pneumotropic influenza A virus: implications for influenza-associated 
encephalopathy. Biol Chem 2004;385:487–92. 
 17 
[19] Yamamoto T, Tanaka H, Kobayashi H, Okamura K, Tanaka T, Emoto Y, et al. 
Retrospective review of Japanese sudden unexpected death in infancy: the 






Genotypic distribution of CPT 2 gene polymorphisms. 
Type Genotypes Alleles No. (%)  
 F352C V368I  SUDI 
(n = 54) 
Control 
(n = 200)  
A FF VV FV–FV 4 (7.4) 15 (7.5) 
B FF II FI–FI 11 (20.4) 60 (30.0) 
C FF VI FV–FI 18 (33.3) 68 (34.0) 
D CC II CI–CI 6 (11.1) 7 (3.5) 
E FC II FI–CI 9 (16.7) 32 (16.0) 





F352C and V368I allelic frequency. 
Polymorphism Allele No. (%)  OR (95% CI) p value 
  SUDI 
(n = 54)  
Control 
(n = 200) 
  
F352C F 81 (75.0) 336 (84.0) 1.75 (1.05-2.92) 0.030 
 C 27 (25.0) 64 (16.0)   
V368I V 32 (29.6) 116 (29.0) 0.97 (0.61-1.55) 0.898 
 I 76 (70.4) 284 (71.0)   




CI haplotypes among the SUDI and the control groups. 




(n = 54) 
Control 
(n = 200) 
2 6 (11.1) 7 (3.5) 
1 15 (27.8) 50 (25.0) 




F352 wild/Hetero- and homozygocity among the SUDI and the control groups. 
F352C 
zygocity 
No. (%)   OR (95% CI) p value 
SUDI 
(n = 54)  
Control 
(n = 200) 
  
Wild/Hetero 48 (88.9) 193 (96.5) 3.45 (1.11-10.73) 0.036 
Homo 6 (11.1) 7 (3.5)   
Abbreviations: CI, confidence interval; OR, odds ratio. 
 
 
